Pegasys (pegylated interferon α -2a)

P1, N=132, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting

P1/2, N=17, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed | N=34 --> 17

P2, N=96, Recruiting, Omico | Not yet recruiting --> Recruiting

P2, N=96, Completed, Shanghai HEP Pharmaceutical Co., Ltd. | Recruiting --> Completed

Prior to ropeginterferon-alfa, the participants were managed with therapeutic phlebotomies, or cytoreduced with either hydroxyurea, pegylated interferon-alpha 2a ( Pegasys), JAK2 inhibitors, or were newly diagnosed and previously untreated. Ropeginterferon-alfa is effective in PV and ET, however, the dose that achieves CHR is highly individualized, necessitating an incremental titration approach. The patients already in CHR from prior therapy needed relatively lower doses of ropeginterferon-alfa to maintain CHR. Clinical trials are ongoing with an alternate accelerated dosing scheme and results are awaited.

P1, N=2, Terminated, University of Nebraska | N=30 --> 2

P1, N=132, Not yet recruiting, Bristol-Myers Squibb

Here, we report the primary endpoint results of xalnesiran, a small interfering ribonucleic acid (siRNA) targeting the HBsAg coding region of the HBV genome (RO7445482, RG6346) in combination with nucleos(t)ide analogues (NUC), with or without an immunomodulator: pegylated interferon alfa-2a (Peg-IFN-α, Pegasys®), or ruzotolimod (toll-like receptor 7 agonist, RO7020531, RG7854). Xalnesiran combination therapies of 48 wks treatment duration were generally safe and well tolerated. Higher HBsAg loss rates were observed when xalnesiran was combined with an immunomodulator (PegIFN-α or ruzotolimod).

P2, N=324, Recruiting, Royal Marsden NHS Foundation Trust | Trial completion date: Aug 2024 --> Sep 2026 | Trial primary completion date: Aug 2023 --> Sep 2026

P2, N=60, Completed, Australasian Leukaemia and Lymphoma Group | Recruiting --> Completed

P2, N=96, Not yet recruiting, Omico

P2, N=68, Recruiting, Zealand University Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Oct 2023 --> Aug 2025

P2, N=84, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> May 2023 | Trial primary completion date: Jun 2024 --> May 2023

P2, N=324, Recruiting, Royal Marsden NHS Foundation Trust | Not yet recruiting --> Recruiting

Ruxolitinib was discontinued and the patient received two cycles of RR-EPOCH, four cycles of R-COMP and lenalidomide. While this treatment resulted in complete metabolic response, the patient was deemed eligible for CAR-T cell treatment by the lymphoma-board, because of the high-risk features of this lymphoma (immunosuppression associated, high IPI score and double expressor score of 2).After bridging with polatuzumab-vedotin-bendamustin, the patient received axicabtagene ciloleucel on 22.11.2021... Therapy of JAK1/2 inhibitor associated aggressive B-Cell lymphoma is feasible and results in durable remissions with acceptable toxicity.Figure 1DateJAK2 V617F Allelic burden(Sample site: peripheral blood)17.07.20192,108%27.08.20192,038%29.10.20191,37816.10.20200,889%04.03.20210,814%23.08.20210,275%15.09.20210,528%12.01.20221,101%23.02.20220,645%Table 1

Cytoreductive therapy was given to 14 TNT patients (Hydroxycarbamide, n=12; Pegasys, n=1,; Anagrelide, n=1) dictated by physician choice.In evaluable patients with TNT (n=69), NDM was found in only 9 patients (13.2%) and associated with older age (median age 69.3 yr)...We hence favour the term idiopathic thrombocytosis in selected for patients with TNT patients. Further studies are warranted to examine the role of cytoreduction and anti-platelet therapy in TNT in selected patient groups, e.g. previous thrombosis , cardiovascular risk factors, older age and extreme thrombocytosis.

Later, pegylated IFN-α2a (Pegasys) and pegylated IFN-α2b (PegIntron) were introduced, which have since been reported to be better tolerated due to reduced toxicity...Within the hematological malignancies, rIFN-α2 has been used off-label for decades in patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs)-i.e., essential thrombocythemia, polycythemia vera, and myelofibrosis-and in recent years rIFN-α2 has been revived with the marketing of ropeginterferon-α2b (Besremi) for the treatment of polycythemia vera patients...Another rIFN formulation-recombinant interferon-β (rIFN-β)-has been used for decades in the treatment of multiple sclerosis but has never been studied as a potential agent to be used in patients with MPNs, although several studies and reviews have repeatedly described rIFN-β as an effective anticancer agent as well. In this paper, we describe the rationales and perspectives for launching studies on the safety and efficacy of rIFN-β in patients with MPNs.

P1/2, N=510, Recruiting, Hoffmann-La Roche | Trial completion date: Apr 2027 --> Oct 2026 | Trial primary completion date: Oct 2026 --> Apr 2026

P2; N=48; Active, not recruiting; Sponsor: Janssen Research & Development, LLC; Recruiting --> Active, not recruiting

P1/2, N=415, Recruiting, Hoffmann-La Roche | N=255 --> 415

(1) However, recombinant IFN a-2a or IFN a-2b interferon regimens are no longer available and therefore, the pegylated analogue (pegylated IFN a-2a, Pegasys; Hoffmann-La Roche) has been currently used. Nevertheless, treatment outcomes have only been reported in case reports and in a few clinical trials.(2)(3)(4) The current study aimed to evaluate the efficacy and safety profile of peg IFN in the treatment of mycosis fungoides (MF).

P2, N=68, Not yet recruiting, Zealand University Hospital | Trial completion date: May 2023 --> Dec 2023 | Initiation date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2023 --> Oct 2023

P2, N=324, Not yet recruiting, Royal Marsden NHS Foundation Trust

P1/2, N=255, Recruiting, Hoffmann-La Roche

P2, N=68, Not yet recruiting, Zealand University Hospital

Notably, some mutations [e.g., p.Asn257Lysfs (c.771_775del)] were observed in unrelated populations. Thus, seemingly genotyping recurring BRCA PSVs in specific populations may provide first pass BRCA genotyping platform.

P1, N=158, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed

P1, N=158, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Aug 2019 --> Nov 2019 | Trial primary completion date: Aug 2019 --> Nov 2019

P1; N=158; Active, not recruiting; Sponsor: Hoffmann-La Roche; Trial completion date: Feb 2019 --> Aug 2019; Trial primary completion date: Feb 2019 --> Aug 2019